ESOPApr 26, 2026, 05:29 AM
NXTC Annual Meeting to Vote on ESOP Share Increase
AI Summary
NextCure, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on June 18, 2026. Key proposals include the election of two Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and the approval of an amendment to the 2019 Omnibus Incentive Plan to increase authorized shares. The company also provided updates on its clinical product candidates, SIM0505 and LNCB74, with data readouts expected in Q2 and H2 2026, respectively.
Key Highlights
- Annual Meeting scheduled for June 18, 2026, virtually.
- Stockholders to vote on increasing shares for 2019 Omnibus Incentive Plan.
- Two Class I directors nominated for election to three-year terms.
- Ernst & Young LLP proposed for auditor ratification for 2026.
- Advisory vote on named executive officer compensation.
- 3,607,555 common shares outstanding as of April 22, 2026.
- SIM0505 Phase 1 data readout expected in Q2 2026.
- LNCB74 Phase 1 trial update expected in H2 2026.
Price Impact
More from NXTC